The presentations feature new data from the Phase 2 VIBRANT trial evaluating verekitug, the only known antagonist to the thymic stromal lymphopoietin (TSLP) receptor currently in clinical development, in chronic rhinosinusitis with nasal polyps (CRSwNP). The data to be presented include the clinical effect of verekitug in participants with CRSwNP and comorbid asthma, as well as its impact on nasal and blood biomarkers.

Presentation details:

  • Presentation Title: Verekitug, a Thymic Stromal Lymphopoietin Receptor Antagonist, Administered in Participants with Chronic Rhinosinusitis with Nasal Polyps and Comorbid Asthma in the VIBRANT Trial

    Presenting Author: Joseph K. Han, MD, Old Dominion University

    Poster Board Number: P1397

    Session: B32 – Rise of the Biologics: A New Hope for Breathing Easier

    Presentation Date and Time: Monday, May 18, 2026 – 11:30 AM – 1:15 PM ET
  • Presentation Title: Verekitug, a Thymic Stromal Lymphopoietin Receptor Antagonist, in Chronic Rhinosinusitis with Nasal Polyps: Effect on Type 2 Inflammatory Biomarkers in the VIBRANT Trial

    Presenting Author: Joseph K. Han, MD, Old Dominion University

    Poster Board Number: P1398

    Session: B32 – Rise of the Biologics: A New Hope for Breathing Easier

    Presentation Date and Time: Monday, May 18, 2026 – 11:30 AM – 1:15 PM ET